LCM
ONCY

Lynwood Capital Management’s Oncolytics Biotech ONCY Stock Holding History

Lynwood Capital Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,000
Closed -$41K – 138
2022
Q4 		$41K Buy
+25,000
New +$38K 0.05% 90

Other funds holding ONCY

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lynwood Capital Management's ONCY Position: Q1 2023 in Review

Lynwood Capital Management sold out of Oncolytics Biotech (ONCY) in Q1 2023, closing a stake of 25,000 shares — an estimated $41K sold.

Lynwood Capital Management first reported a position in ONCY in Q4 2022 and held it in 1 quarter. The position peaked at $41K in Q4 2022. 33 funds tracked by Wall St. Rank hold ONCY as of Q1 2023.

  • Lynwood Capital Management reported no remaining Oncolytics Biotech position as of Q1 2023 after selling out during the quarter.
  • Lynwood Capital Management sold 25,000 Oncolytics Biotech shares in Q1 2023, an estimated $41K.
  • Lynwood Capital Management first reported a position in Oncolytics Biotech in Q4 2022 and held it in 1 quarter.
  • Lynwood Capital Management's Oncolytics Biotech position peaked at $41K in Q4 2022.
  • 33 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2023.

Based on Lynwood Capital Management's 13F filing for Q1 2023, filed 12 May 2023.